Fig. 3: Cross-validation of the LC–MS/MS and qMSI. | Molecular Psychiatry

Fig. 3: Cross-validation of the LC–MS/MS and qMSI.

From: Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood–brain barrier

Fig. 3

a, b Scatter dot plots showing LC–MS/MS and MALDI-qMSI-based quantitation of steady-state total brain tissue and plasma concentrations and c, d the total brain slice and buffer concentrations collected after performing in vivo experiments (n = 6 per group) and in vitro experiments (n = 3 per group), respectively. Kp,brain (e) and Kp,uu,brain (f) values determined using the conventional CMA method (LC–MS/MS) and MALDI-qMSI. Error bars represent standard deviations from the mean. Total concentrations (Ctot,brain,ss) for the in vivo samples were analyzed in half of the brain (LC–MS/MS), and in the coronal section of the second half of the brain (MALDI-qMSI). Total concentrations (Ctot,br.slice,ss) from the in vitro study were analyzed either in the entire brain slice (LC–MS/MS) or in the coronal section of the brain slice (MALDI-qMSI). RISP risperidone, CLZ clozapine, OLZ olanzapine. NB: a semilogarithmic scale is used in panels b, c, e, and f.

Back to article page